Clinical trial NCT06705868: Chrononutrition/ Chronotoxicity Intervention in People With Metabolic-associated Steatotic Liver Disease.
Official title: Time-restricted Eating in Patients With Metabolic-associated Steatotic Liver Disease . CHRONOMASLD: A Chrononutrition/Chronotoxicity Randomized Controlled Trial.
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: MASLD
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
NAFLD
NAFLD - Non-Alcoholic Fatty Liver Disease
NAFLD (Nonalcoholic Fatty Liver Disease)
Keywords: non alcoholic fatty liver disease (NAFLD)
chrononutrition
intermittent fasting
randomized controlled trial (RCT)
chronotoxicity
time restricted eating
MASLD
Metabolic Dysfunction-Associated Steatotic Liver Disease
Lead sponsor: Cyprus University of Technology
Sponsor class: OTHER
Collaborators: name: Cyprus State Heath Organization Services
First posted: 2024-11-26
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to study the effect of a time-restricted eating (TRE) dietary pattern combined with a time of consumption restriction about the daily portions of fruits and vegetables in people diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD).

The protocol of the study is an intention to treat protocol. The main research questions are:

1. Does compliance in a TRE dietary scheme (positively) affect changes in body weight and body fat mass in people diagnosed with MASLD?
2. Does an additional time restriction on the consumption of fruits and vegetables within the "light-window" of the day affects the metabolism of food contaminants?

Participants will be asked to:

1. Adhere to a TRE dietary pattern for 3 months. TRE consists of an 8-hour eating vs 16 hours fasting within the day. First meal of the day should occur within an hour after wake-up time and last meal of the day should occur not later than 2 hours before bed-time.
2. Adhere to a further time restricted consumption of a "5-a-day" portions of fruits and vegetables between the "light-window hours" between 9am to 4pm.
3. Visit the Nutrition \& Dietetics Clinic once every month for anthropometric measurements (on 4 time points).
4. Collect and deliver first morning urine samples (on 7 time points).
5. Collect and deliver saliva samples at baseline and at the end of the trial (Saliva collection should occur every 4-hours for 48-hours including fasting collection at baseline and at the end of three months)

5) Complete a compliance and lifestyle questionnaire questionnaire via telephone interview to the research team every 2 weeks.

6) Share photos to the research team with the use of an application on time of actual fruit and vegetables consumption, 3-4 times per week throughout the study protocol.

Researchers will compare the designed intervention package of this TRE with the Standard of Care (SoC) protocol (based on the international guidelines) that is currently used in daily practice for the management of MASLD.

Detailed description: This parallel-arm, randomized controlled trial (RCT) will study the effects of an ad libitum TRE dietary pattern (8 hours eating, 16 hours fasting) with an additional restriction regarding the fruit and vegetable consumption on health parameters, pesticide metabolism and concomitant toxicity in MASLD patients compared with the Standard of Care (SoC) approach, that will serve as the control group. Participants will be asked to consume all meals/snacks during the 8 hours daily period that they will select for themselves without any further dietary advice regarding caloric or other macronutrient intake. However, participants will be instructed that their first meal of the day will have to occur an hour after wake-up hour and will also be asked to have their last meal at least 2 hours earlier than bedtime (actual time of sleep). Additionally, participants will have to consume 5 portions (400g) of fruits and vegetables within time-window for fruit \& vegetable consumption earlier in the day; from 9am to 4pm.

Non-caloric beverage consumption (water, black coffee, unsweetened tea, non-sweetened beverages) will be allowed within the restricted hours of the intervention.

Participants allocated in the SoC group (control) will receive oral and written SoC lifestyle advice from a registered dietitian. The SoC advice is based on the EASL/EASD/EASO joint Clinical Practice Guidelines for the management of MASLD. Patients will receive guidance on a) energy restriction, b) weight reduction, c) the macronutrient composition of the diet, d) limitation of alcohol intake (below the risk threshold of 30g/d and 20g/day for men and women, respectively) and e) increase their physical activity levels. Additionally, in this study patients will be asked to consume standard "5-a-day" portions of fruits and vegetables daily, as part of their dietary healthier behaviour.

Eligibility criteria: Inclusion Criteria:

1. Body mass index 25 (±0,5)-45(±0,5) kg/m2
2. Clinical diagnosis of MASLD, not excluding undiagnosed NASH or with NASH stage F0-F1
3. Self-reported habitual eating period more than or equal to 14 h per day, BUT NOT LESS.
4. Cyprus inhabitants of for at least 1 year
5. Registered to the National Health System of the Republic of Cyprus (Gesy

Exclusion Criteria:

1. Night Shift worker
2. Fasting \>12-h/day more than once a week or \> once a week no food intake after 18:00
3. Co-existing causes of chronic liver disease according to standard diagnostic testing including, but not restricted to:

   1. Positive hepatitis B surface antigen
   2. Positive hepatitis C virus RNA
   3. Suspicion of drug-induced liver disease
   4. Alcoholic liver disease
   5. Autoimmune hepatitis
   6. Wilson's disease
   7. Hemochromatosis
   8. Primary biliary cholangitis or primary sclerosing cholangitis
   9. Known or suspected hepatocellular carcinoma
4. Medications which cause liver disease or secondary hepatic steatosis (Tamoxifen, systemic corticosteroids, methotrexate, tetracycline, estrogens, valproic acid, and statin (registration is possible if statin is delivered in a consistent dosage within 12 weeks)
5. Current or recent history (\<5 years) of significant alcohol intake (\>30g of alcohol/ day or \>210g/week for men, \>20g of alcohol/day or \>140g/week for women)
6. Doctor diagnosed diabetes mellitus on medication or insulin
7. Severe medical comorbidities \[ischemic heart disease, 3rd degree atrioventricular block, chronic obstructive pulmonary disease, severe hypertension (blood pressure \>200/120 mmHg)\]
8. Unstable weight (\>5% change in the last 2 months) or participation in a weight-loss program within the past 12 weeks
9. Sleep disorder (with a medical diagnosis) or individuals self-reporting sleep difficulties and poor sleep \[average sleep less than 6 consecutive hours or patients who systematically experience sleep interruption for more than 2 times each night (waking up for toilet use is not to be considered sleep interruption)\]
10. Individuals with food allergies (or hypersensitivity to the fruits and vegetables that will be selected for the study)
11. Systematic organic products consumers (defined as a self-reported usual consumption of more than 80% of their weekly fruits \& vegetables being organic)
12. Pregnant or trying to become pregnant or lactating women
13. People not in position to communicate in Greek or English language
14. Having metallic parts in the body

Primary outcomes:
measure: Changes in body weight
timeFrame: From enrolment to the end of treatment at 3 months (with two in-between measurement)
measure: Changes in body fat mass
timeFrame: From enrolment to the end of treatment at 3 months (with one in-between measurement)
Secondary outcomes:
measure: Changes in Pesticide Metabolite 3-phenoxybenzoic Acid (3-PBA) Levels in Urine
timeFrame: From first day of the intervention to the end of treatment at 3 months (with six in between measurements)
measure: Changes in Pesticide Metabolite 6-chloronicotininc Acid (6-CN) Levels in Urine
timeFrame: From first day of the intervention to the end of treatment at 3 months (with six in between measurements)
measure: Changes in waist circumference (WC)
timeFrame: From enrolment to the end of treatment at 3 months (with one in-between measurement)
measure: Changes in 4-Hydroxynonenal (4HNE) Levels in Urine
timeFrame: From first day of the intervention to the end of treatment at 3 months (with six in between measurements)
measure: Changes in Body Mass Index (BMI)
timeFrame: From enrolment to the end of treatment at 3 months (with two in-between measurement)
measure: Changes in glucose (Gluc) levels in blood
timeFrame: From enrolment to the end of treatment at 3 months (one measurement at the beginning and one measurement at the end of the intervention)
measure: Changes in total cholesterol (TC) levels in blood
timeFrame: From enrolment to the end of treatment at 3 months (one measurement at the beginning and one measurement at the end of the intervention)
measure: Changes in high-density lipoprotein cholesterol (HDL) levels in blood
timeFrame: From enrolment to the end of treatment at 3 months (one measurement at the beginning and one measurement at the end of the intervention)
measure: Changes in low-density lipoprotein cholesterol (LDL) levels n blood
timeFrame: From enrolment to the end of treatment at 3 months (one measurement at the beginning and one measurement at the end of the intervention)
measure: Changes in alanine transaminase (ALT) levels n blood
timeFrame: From enrolment to the end of treatment at 3 months (one measurement at the beginning and one measurement at the end of the intervention)
measure: Changes in aspartate aminotransferase (AST) levels in blood
timeFrame: From enrolment to the end of treatment at 3 months (one measurement at the beginning and one measurement at the end of the intervention)
measure: Changes in C-Reactive Protein (CRP) levels n blood
timeFrame: From enrolment to the end of treatment at 3 months (one measurement at the beginning and one measurement at the end of the intervention)
Other outcomes:
measure: Changes in other pesticide biomarkers in urine
timeFrame: From first day o the intervention to the end of treatment at 3 months (with six in between measurements)
measure: Changes in other biomarkers of oxidative stress in urine
timeFrame: From first day o the intervention to the end of treatment at 3 months (with six in between measurements)
Locations:
city: Limassol
country: Cyprus
facility: Limassol General Hospital
Study officials:
References: